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Chondrosarcoma with additional mesenchymal 
component 
Note 
Dedifferentiated chondrosarcoma was first proposed in 
1971 by Dahlin and Beabout.  
It is characterized by two distinct histopathological 
components; a well-differentiated benign chondral 
lesion or chondrosarcoma (any grade) sharply 
juxtaposed with a high-grade non-cartilaginous 
component; typically there is an abrupt transition 
between the two tissue types. The non-cartilaginous 
component of dedifferentiated chondrosarcoma is 
generally an osteosarcoma, a fibrosarcoma, or a 
malignant fibrous histiocytoma. Dedifferentiation to 
leiomyosarcoma, giant cell tumor, and rarely, clear-cell 
chondrosarcoma or rhabdomyosarcoma has been 
reported. 
Clinics and pathology 
Disease 
Dedifferentiation is a process in which a benign or low-
grade malignant tumor undergoes transformation to a 
high-grade tumor. This process is well-known in 
cartilaginous tumors such as chondrosarcomas; 
exceptionally, it has been reported in low-grade 
osteosarcoma, chordoma and giant cell tumor.  
The rate of dedifferentiation among chondrosarcomas 
ranges from 7%-20%.  
The rate of dedifferentiation is 13%-15% in central 
chondrosarcomas compared to 4%-5% in peripheral 
chondrosarcomas. 
Note 
Pathogenesis unclear. Dahlin and Beabout suggested 
that dedifferentiation is the result of direct 
transformation of a well-differentiated cartilage lesion, 
while others suggested that it is related to 
transformation within the dense fibrotic reaction 
surrounding necrotic areas at the margin of the 
chondral component by a process analogous to the 
development of fibrosarcomas in bone infarcts and 
chronic osteomyelitis.  
Others advocate that dedifferentiation is the result of 
two differing clones of cells, one of which 
differentiates into a low-grade chondrosarcoma, while 
the other fails to differentiate and displays features of a 
high-grade sarcoma. 
Epidemiology 
Dedifferentiated chondrosarcoma accounts for 
approximately 10% of all chondrosarcomas and shows 
an increased growth rate and rapid metastatic spread in 
comparison with ordinary chondrosarcomas.  
It arises most frequently in the 5th and 6th decade of 
life.  
Anatomically, the femur, pelvis and humerus are the 
most common sites of involvement. 
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A. Photomicrograph (stain, hematoxylin and eosin; original magnification, 10x) shows abrupt transition between a low grade 
chondrosarcoma (left) and a high grade spindle cell sarcoma (right). B. Photomicrograph (stain, hematoxylin and eosin; original 
magnification, 2x) shows abrupt transition between a low grade chondrosarcoma (left) and a high grade spindle cell sarcoma (right). 
 
Clinics 
Clinical symptoms include pain, swelling, palpable 
tumor masses and a high rate (30%) of pathological 
fractures.  
Approximately 20% of patients have metastases at 
diagnosis.Radiographically, dedifferentiation is 
suggested by a sharply demarcated area of aggressive 
bone destruction associated with an underlying 
cartilaginous lesion and the presence of an extraosseous 
soft-tissue mass. Three radiographic types of 
dedifferentiated chondrosarcoma have been described.  
In type 1, the radiographic appearance is the same as 
for a central chondrosarcoma, with the addition of a 
region with very aggressive bone destruction. 
In type 2, lesions resemble an underlying benign 
enchondroma but also have destructive changes and/or 
a large soft tissue mass. In type 3, lesions are not 
distinctive radiographically and present as a very high-
grade destructive lesion of bone.  
The dedifferentiated component can easily be detected 
by MRI, as a sharply defined osteolytic area of reduced 
signal intensity adjacent to the hyperintense chondral 
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component corresponding to regions of 
dedifferentiation.  
Three distinct MRI patterns have been described. In the 
first, there is clear demarcation between the two 
regions of high and reduced T2-weighted signal 
intensity, a so-called biphasic pattern. This pattern 
typically correlates with a type 1 radiographic lesion. In 
the second pattern, the only MRI evidence of an 
underlying chondral lesion is the presence of multiple 
areas of signal void corresponding to matrix 
mineralization identified radiographically; this 
indicates the presence of underlying or residual 
enchondromas, and correlates with a type 2 
radiographic lesion. In the third MRI pattern, the vast 
majority of the lesion has a relatively reduced signal 
intensity compared with typical chondral tissue and a 
diagnosis of an underlying chondral component could 
not be made on MRI. In this case, smaller areas of 
hyperintensity on T2-weighted images could be seen 
within the main tumor mass. These presumably 
correspond to tumor necrosis rather than chondral 
tissue, and correlate with a type 3 radiographic lesion. 
Pathology 
Macroscopically, both cartilaginous and 
noncartilaginous tumor components, typically, are 
grossly evident in varying proportions.  
The blue-grey lobulated low grade cartilaginous 
component is usually located centrally, while the 
overgrowth and expanded fleshy or haemorrhagic 
higher grade component is predominantly extraosseous.  
Microscopically, there is abrupt demarcation between 
the two components. 
Treatment 
Surgical: Chondrosarcomas are a surgical disease. 
High grade (grade 2 and 3) and dedifferentiated 
chondrosarcomas should be managed with wide 
resection. Chondrosarcomas of the pelvis and spine can 
be particularly difficult to treat due on the size of the 
tumor and its relationship to important adjacent 
structures such as the bladder or spinal cord; 
intralesional or marginal resection margins, and local 
recurrences are the highest in this group of patients 
with axial tumors. 
Non-surgical: The role of chemotherapy remains 
unclear. A poor 5-year survival and no difference in 
overall survival between patients managed with surgery 
alone (11.8%) and those managed with a combination 
of surgery and chemotherapy (4%) has been reported. 
Others recommended immediate surgical removal of 
the lesions and postoperative chemotherapy if possible 
to prevent metastatic spread of the disease. Given the 
poor prognosis of patients with dedifferentiated 
chondrosarcoma, National Comprehensive Cancer 
Network (NCCN) guidelines suggest treating 
dedifferentiated chondrosarcoma in a fashion similar to 
osteosarcoma. Radiation therapy can be considered (1) 
after incomplete resection, aiming at maximal local 
control (curative), (2) if resection is not feasible or 
would cause major morbidity (palliative). 
 
 
Radiograph (left) and CT (right) show osteolysis and destruction of the cortex of the humeral diaphysis of a 60-year-old man with a 
known enchondroma of the humerus. 
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Tumor specimen after en bloc resection of the proximal humerus. 
 
Targeted treatments: A phase II trial investigates the 
use of perifosine, a modulator of membrane 
permeability, in patients with chemotherapy insensitive 
tumors including chondrosarcomas. Novel anti-folates, 
such as pemetrexed, are currently under active 
investigation in patients with chondrosarcoma, as is the 
combination of gemcitabine and docetaxel. Finally, 
small-molecule inhibitors, such as dasatinib, and 
monoclonal trail antibodies against the TNF-related 
apoptosis, such as Apomab (TRAIL-receptor agonist), 
are also being explored and now are entering the 
clinical trial arena. 
Prognosis 
The average time from diagnosis to the onset of 
metastatic disease is usually short. The anatomical site 
of metastases is the lungs (70-82%), the viscera (20%) 
and the skeleton (10%). Histologically, metastases 
consist only of the high-grade anaplastic component. 
There is no uniform guideline for the treatment of 
metastases. 
The prognostic factors for patients with dedifferentiated 
chondrosarcomas are vague; metastatic disease at 
diagnosis, malignant fibrous histiocytoma 
dedifferentiation, and a high percentage of 
dedifferentiated component were related to poorer 
outcomes. Early diagnosis at a localized stage of 
disease through a careful biopsy and adequate surgical 
treatment may improve the survival of these patients. 
Metastatic disease at presentation is a strong negative 
predictive factor of patient survival. Tumor location at 
the pelvis has been reported as an independent risk 
factor for metastases and death. 
Local recurrence and the histology of the 
dedifferentiated component have also been noted to be 
independent risk factors for metastases and death. 
Malignant fibrous histiocytoma dedifferentiation had a 
significantly worse prognosis compared with patients 
who had an osteosarcoma dedifferentiation. The rate of 
local recurrence seems to depend on the margins of 
tumor resection; as expected, radical or wide resection 
is associated with lower local reccurrence rates 
compared to inadequate resection. However, local 
tumor control does not seem to be related to a better 
rate of survival. 
Genetics 
Note 
Controversy remains as to whether the anaplastic and 
cartilaginous components are derived from a common 
precursor cell, or whether they represent separate 
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genotypic lineages (collision tumour). Molecular, 
genetic and epigenetic studies show that both tumor 
components share some genetic alterations; two clones 
derive from a single precursor but a substantial number 
of genetic alterations occur after the diversion of the 
two components, indicating that these two clones are 
separated in the early phases of the disease progress 
and further alterations are responsible for the "switch" 
to a high-grade anaplastic sarcoma. 
Cytogenetics 
Note 
Cytogenetic data available at present suggest that no 
specific aberrations seem to be associated with 
dedifferentiated chondrosarcoma. Structural and 
numerical aberrations are most frequently reported for 
chromosomes 1 and 9. The non-uniform karyotype is 
reflecting the wide variety of histology of the 
"dedifferentiated" part. Based upon mutation analysis 
of TP53, it was shown that both components - sharing 
identical and uncommon TP53 mutations - have a 
common origin, though the apparent numerous 
additional genetic differences suggest an early division 
of the two cell clones. 
Cytogenetics Molecular 
Dedifferentiated chondrosarcoma has a strong 
tumorigenicity and shows chondroblastic and 
osteoblastic characteristics in vitro and in vivo. The 
expression of PPAR-γ might have contributed to the 
multifunctional property of the cell line. This cell line 
showed extremely complicated karyotype based on 
cytogenetic analysis. Although no specific 
chromosomal abnormality has yet been identified; a 
part of the chromosome commonly demonstrated a 
repeated numerical aberration of +7, +8, +20, and +21. 
In addition, this cell line shared a part of cytogenetic 
findings with chondrosarcoma and osteosarcoma. 
Genes involved and proteins 
Note 
Tumor suppressor gene mutations may play a major 
role in the development, progression, and /or 
differentiation of tumors. 
P53 gene: Mutations of p53 occur frequently in the 
oncogenesis of various mesenchymal neoplasms. Some 
authors reported that p53 overexpression was 
consistently present in dedifferentiated components 
with accompanied increased proliferative activity and 
an absence in low-grade cartilaginous component. It 
has been documented that the overexpression of p53 
measured immunohistochemically is usually due to the 
accumulation of the mutated gene product, which 
exhibits a longer half-life than the wild-type protein. 
Recent genetic analyses revealed that p53 mutations 
were detected exclusively in dedifferentiated 
components. 
Ras-genes: Activating mutations in ras genes (K-ras, 
H-ras, and N-ras) usually at codons 12, 13 and 61 are a 
common genetic abnormalities in human malignancies. 
Among the patients with dedifferentiated 
chondrosarcomas, those with H-ras mutation tended to 
have a worse prognosis than those without. Therefore, 
H-ras mutation may occur during the course of 
dedifferentiation and may also have some effect on 
malignant potential. 
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